Flu Antiviral Prescriptions for US Kids Plunge During COVID: A Study Reveals Troubling Trends
The COVID-19 pandemic has significantly impacted healthcare practices, and a recent study sheds light on a concerning trend in antiviral prescriptions for children at high risk of severe influenza. Despite an increase in clinical testing for influenza among children, the rate of antiviral prescriptions in emergency departments (EDs) has plummeted by over half during the late pandemic period compared to pre-pandemic times.
The Study's Findings:
- Researchers analyzed data from seven US academic pediatric hospitals, focusing on children who tested positive for influenza and were at high risk for severe complications. They found that the rate of antiviral prescriptions dropped from 32.2% pre-pandemic to 15.6% during the late pandemic, a 53% relative decrease.
- The study revealed a strong correlation between timely testing and antiviral treatment. Children who were tested and seen within two days of symptom onset were 17.20 times more likely to receive antivirals compared to those not tested. Even those seen after two days of symptom onset had a 4.08 times higher odds of receiving antivirals.
- Interestingly, despite increased testing, the odds of being prescribed antivirals were significantly lower during the late pandemic (aOR: 0.17) compared to the pre-pandemic period.
Implications and Recommendations:
The authors emphasize the importance of addressing this discrepancy between testing and treatment. They suggest that promoting guideline-concordant antiviral prescribing is crucial, as early treatment can significantly reduce the severity and duration of influenza illness, thereby lowering the risk of complications and hospitalizations.
Limitations and Future Directions:
The study acknowledges limitations, including the lack of data on prescription fills and caregiver acceptance. The authors also highlight potential unmeasured confounders such as pandemic misinformation, ED workload, medication costs, and parental concerns about adverse effects. Future research should explore these factors to gain a comprehensive understanding of the trends observed.
This study raises important questions about the effectiveness of antiviral prescription management in EDs during the pandemic. It underscores the need for further investigation and potential adjustments to clinical guidelines to ensure optimal protection for vulnerable pediatric patients from avoidable influenza morbidity.
